Slovakia will approve Tesla's autonomous driving technology
路透社2026/10/08 10:46Reuters, October 8 – Slovakia is expected to approve Tesla’s TSLA.O Full Self-Driving (FSD) system within a few days, according to a video posted Wednesday afternoon on LinkedIn by Transport Minister Jozef Ráž. This move will make Slovakia the ninth EU country to approve this driver-assistance technology. "Data shows these vehicles reduce accident rates, and that is our goal," he stated. Ráž said the ministry would send a letter of recognition to the Netherlands, where the Dutch regulator RDW approved the system earlier this year and acts as the main supervisory body for Tesla’s European approval process. "Once this letter is delivered, the FSD system can also be used here. But remember: you are still the driver and remain responsible for the vehicle. We do this for your safety," Ráž said in the video. The minister's comments closely followed a Reuters report detailing how Tesla lobbied for FSD approval in Europe by framing regulators as barriers to advancing road safety technology. Several European countries, including the Czech Republic, Slovenia, and Denmark, have approved the use of the system earlier this year. An EU-wide vote on FSD could take place as early as December. (For the convenience of non-English speakers, Reuters automatically translates its reports into several other languages. Since automated translation may be incorrect or may not provide the necessary context, Reuters does not guarantee the accuracy of automated translation and provides it purely as a convenience for readers. Reuters assumes no responsibility for any damage or loss caused by use of automated translations.)
Reuters, October 8 - Slovakia is expected to approve Tesla's TSLA.O Full Self-Driving (link) (FSD) system within days, Transport Minister Jozef Raz said in a video posted on LinkedIn on Wednesday afternoon. This move will make Slovakia the ninth EU country to approve the driver assistance technology.
"Data show that these cars have reduced accident rates, and that is exactly our goal," he said.
Raz stated that the ministry will send a letter of recognition to the Netherlands, where the Dutch RDW regulator approved (link) the system earlier this year and serves as Tesla's main supervisory authority in the European approval process (link).
"Once this letter is delivered, the FSD system can also be put into use here. But remember: you are still the driver and are responsible for the vehicle. We are doing this for you," Raz said in the video.
The minister's remarks come shortly after a Reuters report (link) detailed how Tesla has been pressuring European regulators to approve the FSD system by portraying regulators as obstacles to improving road safety technologies.
Several European countries, including the Czech Republic (link), Slovenia (link), and Denmark (link), have approved the system for use earlier this year.
An EU-wide vote on FSD could be held as early as December (link).
(To facilitate non-native English speakers, Reuters has automated the translation of its reports into several other languages. Because automated translation may contain errors or lack required context, Reuters does not guarantee the accuracy of the automated text and provides these translations merely for readers’ convenience. Reuters accepts no responsibility for any damage or loss caused by use of automated translation.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Forex Today: US flash Consumer Sentiment and Canadian jobs in the limelight
Malaysian Ringgit: Fiscal anchor case – MUFG
Nasdaq Drops Over 300 Points After OpenAI's Revenue Comes In $20 Billion Short
BUZZ-Revolution Medicines stock drops due to concerns over pancreatic cancer drug data
On October 8, Revolution Medicines (RVMD.O) shares fell 8.1% in afternoon trading to $185.91. RBC Capital Markets stated that the share price decline appeared to be driven by the latest U.S. Food and Drug Administration (FDA) review documents regarding the company's pancreatic cancer drug Rasonque, particularly the disclosure of objective response rate data for specific RAS mutation subgroups. RBC pointed out that overall survival, rather than objective response rate, is a more meaningful indicator of efficacy, and that the sell-off overlooked Rasonque's broad activity across a variety of RAS mutation subgroups. RBC stated: "While we acknowledge that today's share price decline takes place against the backdrop of overall weakness in the biotech sector, we still believe that the market's reaction to the FDA review documents is an overreaction, given that the drug was approved on the basis of highly clinically meaningful efficacy and has received positive feedback from physicians." Including intraday fluctuations, the stock has more than doubled year-to-date. (Note: For the convenience of non-English speakers, Reuters has automatically translated its reports into several other languages. Automated translations may be inaccurate or lack necessary context; Reuters does not guarantee the accuracy of these automated translations and provides them only for reader convenience. Reuters does not accept liability for any damage or loss arising from the use of automated translation features.)
Crypto prices
More
